Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na+]c/ROS-pathway in human endothelial cells-Reference-Cited by-同舟云学术

Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na+]c/ROS-pathway in human endothelial cells

Published:2022-02 Issue: Volume:146 Page:112515
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Uthman Laween,Li Xiaoling,Baartscheer Antonius,Schumacher Cees A.,Baumgart Patricia,Hermanides Jeroen,Preckel Benedikt,Hollmann Markus W.,Coronel Ruben,Zuurbier Coert J.,Weber Nina C.

Funder

China Scholarship Council

Boehringer Ingelheim

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference20 articles.

1. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease;Jia;Diabetologia,2018

2. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-reduced;Ferreira;J. Am. Coll. Cardiol.,2021

3. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation;Kolijn;Cardiovasc. Res.,2021

4. Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor alpha-stimulated human coronary arterial endothelial cells;Uthman;Cell Physiol. Biochem.,2019

5. Sodium glucose co-transporter 2 inhibitors ameliorate endothelium barrier dysfunction induced by cyclic stretch through inhibition of reactive oxygen species;Li;Int. J. Mol. Sci.,2021

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empagliflozin in Acute Myocardial Infarction Reduces No-Reflow and Preserves Cardiac Function by Preventing Endothelial Damage;JACC: Basic to Translational Science;2024-08

2. Crucial role for sensory nerves and Na/H exchanger inhibition in dapagliflozin- and empagliflozin-induced arterial relaxation;Cardiovascular Research;2024-07-26

3. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2;Basic Research in Cardiology;2024-07-24

4. Empagliflozin enhances cisplatin activity in chemo-resistant EJ138 bladder cancer cells: The importance of anti-diabetic medications in cancer treatment;2024-07-22

5. SGLT2 inhibitors attenuate endothelial to mesenchymal transition and cardiac fibroblast activation;Scientific Reports;2024-07-16